Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of rho kinase activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 707-716

  Rajagopalan, Lakshman E ^a   Davies, Michael S ^a   Kahn, Larry E ^a   Kornmeier, Christine M ^a   Shimada, Hideaki ^a   Steiner, Toni A ^a   Zweifel, Ben S ^a   Wendling, Jay M ^a   Payne, Maria A ^a   Loeffler, Richard F ^a   Case, Brenda L ^a   Norton, Monica B ^a   Parikh, Mihir D ^a   Nemirovskiy, Olga V ^a   Mourey, Robert J ^a   Masferrer, Jaime L ^a   Misko, Thomas P ^a   Kolodziej, Stephen A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL 3 (([4 PYRIDIN 4 YLBENZOYL]AMINO)METHYL)BENZAMIDE; RHO KINASE; RHO KINASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL ASSAY; CELL INFILTRATION; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; LYMPHOCYTE MIGRATION; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOCYTE SHAPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; BIOLOGICAL AVAILABILITY; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL MOVEMENT; CHEMOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HUMANS; INFLAMMATION; INTERLEUKIN-8; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MALE; MYOSIN LIGHT CHAINS; NEUTROPHIL ACTIVATION; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RECEPTORS, CCR2; RHO-ASSOCIATED KINASES;

EID: 77952418153     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166033     Document Type: Article

References (40)

1. Akiyama N, Naruse K, Kobayashi Y, Nakamura N, Hamada Y, Nakashima E, Matsubara T, Oiso Y, and Nakamura J (2008) High glucose-induced up-regulation of Rho/Rho-kinase via platelet-derived growth factor receptor-β increases migration of aortic smooth muscle cells. J Mol Cell Cardiol 45:326-332.
2. Anwar KN, Fazal F, Malik AB, and Rahman A (2004) RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of IκB kinase β and phosphorylation of RelA/p65. J Immunol 173:6965-6972. (Pubitemid 39541085)
3. Beck GC, Yard BA, Breedijk AJ, Van Ackern K, and Van Der Woude FJ (1999) Release of CXC-chemokines by human lung microvascular endothelial cells (LMVEC) compared with macrovascular umbilical vein endothelial cells. Clin Exp Immunol 118:298-303. (Pubitemid 29519263)
4. Deng X, Mercer PF, Scotton CJ, Gilchrist A, and Chambers RC (2008) Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Gαq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol Biol Cell 19:2520-2533.
5. Fox JA, Ung K, Tanlimco SG, and Jirik FR (2002) Disruption of a single Pten allele augments the chemotactic response of B lymphocytes to stromal cell-derived factor-1. J Immunol 169:49-54. (Pubitemid 34686118)
6. Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H, Tocci MJ, O'Keefe SJ, and O'Neill EA (1998) The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37:13846-13853. (Pubitemid 28455562)
7. Haghikia A and Gold R (2010) Sphingosine-1-phosphate and its receptors as a possible therapeutic target in autoimmune diseases of the nervous system. J Neuroimmunol 218:1-2.
8. Hahmann C and Schroeter T (2010) Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci 67:171-177.
9. Haserück N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, and Siess W (2004) The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 103:2585-2592. (Pubitemid 38393011)
10. Henry PJ, Mann TS, and Goldie RG (2005) A Rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction, and airways hyperresponsiveness in allergic mice. Pulm Pharmacol Ther 18:67-74.
11. Herr DR and Chun J (2007) Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 8:155-167.
12. Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, et al. (2009) Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical to clinical translation. J Pharmacol Exp Ther 331:882-895.
13. Kannan N, Haste N, Taylor SS, and Neuwald AF (2007) The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci USA 104:1272-1277. (Pubitemid 46183994)
14. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, et al. (1996) Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho kinase). Science 273:245-248. (Pubitemid 26285892)
15. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, and Ito M (1997) Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 272:12257-12260. (Pubitemid 27203307)
16. Lee H, Lin CI, Liao JJ, Lee YW, Yang HY, Lee CY, Hsu HY, and Wu HL (2004a) Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-κB-dependent mechanism. Am J Physiol Cell Physiol 287:C1657-C1666. (Pubitemid 39507683)
17. Lee JH, Katakai T, Hara T, Gonda H, Sugai M, and Shimizu A (2004b) Roles of p-ERM and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J Cell Biol 167:327-337. (Pubitemid 39435075)
18. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, Tung K, and Tsokos GC (2007) Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 178:1938-1947. (Pubitemid 46154667)
19. Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, Tang L, Hla T, Zeng R, Li L, et al. (2005) Regulation of PTEN by Rho small GTPases. Nat Cell Biol 7:399-404. (Pubitemid 40533130)
20. Lin CI, Chen CN, Chen JH, and Lee H (2006) Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem 99:1216-1232.
21. Lin CI, Chen CN, Lin PW, Chang KJ, Hsieh FJ, and Lee H (2007) Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. Biochem Biophys Res Commun 363:1001-1008. (Pubitemid 47552970)
22. Lock FE and Hotchin NA (2009) Distinct roles for ROCK1 and ROCK2 in the regulation of keratinocyte differentiation. PLoS One 4:e8190.
23. LoGrasso PV and Feng Y (2009) Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 9:704-723.
24. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, and Tsukita S (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140:647-657. (Pubitemid 28134067)
25. Meyer-Schwesinger C, Dehde S, von Ruffer C, Gatzemeier S, Klug P, Wenzel UO, Stahl RA, Thaiss F, and Meyer TN (2009) Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-κB p65 signaling. Am J Physiol Renal Physiol 296:F1088-F1099.
26. Mueller BK, Mack H, and Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4:387-398. (Pubitemid 40704122)
27. Murph M and Mills GB (2007) Targeting the lipids LPA and S1P and their signaling pathways to inhibit tumor progression. Expert Rev Mol Med 9:1-18. (Pubitemid 47617558)
28. Narumiya S (1996) The small GTPase Rho: cellular functions and signal transduction. J Biochem 120:215-228.
29. Noguchi K, Herr D, Mutoh T, and Chun J (2009) Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9:15-23.
30. Salvemini D, Manning PT, Zweifel BS, Seibert K, Connor J, Currie MG, Needleman P, and Masferrer JL (1995) Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric-oxide synthase inhibitors. J Clin Invest 96:301-308.
31. Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, Evenoski CL, Wang T, Mathew B, Husain A, Moitra J, et al. (2010) Differential effects of S1P receptors on airway and vascular barrier function in the murine lung. Am J Respir Cell Mol Biol, doi:10.1165/rcmb.2009-0223OC.
32. Schirok H, Kast R, Figueroa-Pérez S, Bennabi S, Gnoth MJ, Feurer A, Heckroth H, Thutewohl M, Paulsen H, Knorr A, et al. (2008) Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors. ChemMedChem 3:1893-1904.
33. Schröter T, Griffin E, Weiser A, Feng Y, and LoGrasso P (2008) Detection of myosin light chain phosphorylation: a cell-based assay for screening Rho-kinase inhibitors. Biochem Biophys Res Commun 374:356-360.
34. Stanimirovic DB, Wong J, Shapiro A, and Durkin JP (1997) Increase in surface expression of ICAM-1, VCAM-1, and E-selectin in human cerebromicrovascular endothelial cells subjected to ischemia-like insults. Acta Neurochir Suppl 70:12-16. (Pubitemid 127502037)
35. Stavenger RA, Cui H, Dowdell SE, Franz RG, Gaitanopoulos DE, Goodman KB, Hilfiker MA, Ivy RL, Leber JD, Marino JP Jr, et al. (2007) Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J Med Chem 50:2-5. (Pubitemid 46105494)
36. Sun X, Minohara M, Kikuchi H, Ishizu T, Tanaka M, Piao H, Osoegawa M, Ohyagi Y, Shimokawa H, and Kira J (2006) The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 180:126-134. (Pubitemid 44692316)
37. van Buul JD, Voermans C, van Gelderen J, Anthony EC, van der Schoot CE, and Hordijk PL (2003) Leukocyte-endothelium interaction promotes SDF-1-dependent polarization of CXCR4. J Biol Chem 278:30302-30310. (Pubitemid 36962424)
38. Vemula S, Shi J, Hanneman P, Wei L, and Kapur R (2010) ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 115:1785-1796.
39. Vicente-Manzanares M, Cabrero JR, Rey M, Pérez-Martínez M, Ursa A, Itoh K, and Sánchez-Madrid F (2002) A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor-1α-induced lymphocyte actomyosin and microtubular organization and chemotaxis. J Immunol 168:400-410. (Pubitemid 34014142)
40. Wang C, Hayashi H, Harrison R, Chiu B, Chan JR, Ostergaard HL, Inman RD, Jongstra J, Cybulsky MI, and Jongstra-Bilen J (2002) Modulation of Mac-1 (CD11b/CD18)-mediated adhesion by the leukocyte-specific protein 1 is key to its role in neutrophil polarization and chemotaxis. J Immunol 169:415-423. (Pubitemid 34686163)